How do companies that have struck MFN deals see Europe?
The CEOs of three companies have sounded warnings to the region
News
Miscellaneous
National Framework for Plasma-Derived Therapies
SFEE | October 2025
Greek Innovation Fund an important step, but a limited one, says industry
Statement by Michael Himonas, SFEE General Manager, on the Innovation Fund / Transitional Reimbursement Scheme – EURACTIV
Mrs. Ioanna Kontomanolopoulou appointed as Director General of HMVO
HMVO Press Release
Αmendment of the Ministerial Decisions Nr. Δ3(α) 21385/17-5-2021 for the medicinal product Tirosint (07.06.2021)
Αmendment of the Ministerial Decisions Nr. Δ3(α) 21385/17-5-2021 “Cancellation of the Ministerial Decision Δ3(α) 7458/12-2-2019 re the price of the medicinal product Tirosint and will enter into force on 07.06.2021
